课题基金 / 基金详情

Molecular targets of 5FU and combined chemotherapy of 5FU plus low dose CDDP for head and neck cancer

Molecular targets of 5FU and combined chemotherapy of 5FU plus low dose CDDP for head and neck cancer
5FU和5FU加低剂量CDDP联合化疗治疗头颈癌的分子靶点
批准号:
13671812
负责人:
HASEGAWA Yasuhisa
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

HASEGAWA Yasuhisa的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We examined the factors regulating effectiveness of anti-cancer agents especially, 5FU and CDDP, for the purpose of establishing of order-made cancer chemotherapy that will improve prognosis and QOL.Materials and methods : 1) For organ preservation, we administered neoadjuvant 5FU and CDDP chemotherapy (FP) to head and neck cancer patients. 2) We conducted in vitro chemosensitivity tests using histoculture drug response assay (HDRA) on surgical specimens, and performed real-time RT-PCR for the quantitative detection of expression levels of mRNA that may regulate anti-cancer agents. We then analyzed the correlation between them.Results : 1) Among 13 untreated head and neck cancer patients who underwent FP therapy, 10 patients (77%) achieved PR or above. 2) Along with the elevation of HER-2 mRNA expression levels, there was a downward tendency in the inhibition index for 5FU and CDDP in surgical specimens, and we detected a significant upward tendency in HER-2 mRNA expression levels among non-responders of HDRA to 5FU and CDDP.On the other hand, the 5FU inhibition index rose with elevations in COX-2 mRNA expression levels, although the significance of this is unclear. This should be investigated in the future with a greater number of patients.Conclusion : There is a need to analyze the enzyme activity and quantitatively detect expression levels of mRNA for factors relating to metabolism of 5FU. Furthermore, detecting the molecular marker that represents the tumor characteristics in individual patients, we hope to establish order-made cancer chemotherapy that will allow us to select the best regimen for patients through clinical trials. We also hope to apply detection and selection cDNA array to the molecular marker.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Hasegawa Y: "Ghemo-radiotherapy for head and neck cancer"Jpn J Cancer Chemother. 29. 677-683 (2002)
长谷川 Y:“头颈癌的化学放射治疗”Jpn J Cancer Chemother。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Wearable unloading device based on motion support technology
  • 批准号:
    24650381
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
  • 资助金额:
    $2.5万
  • 财政年份:
    2012
  • 负责人:
    HASEGAWA Yasuhisa
  • 依托单位:
Homeostatic enhancement technologies to increase affinity of wearable assistive gear
  • 批准号:
    21686025
  • 项目类别:
    Grant-in-Aid for Young Scientists (A)
  • 资助金额:
    $17.06万
  • 财政年份:
    2009
  • 负责人:
    HASEGAWA Yasuhisa
  • 依托单位:
R&D of wearable powered hand with human finger properties
  • 批准号:
    19760162
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
  • 资助金额:
    $2.43万
  • 财政年份:
    2007
  • 负责人:
    HASEGAWA Yasuhisa
  • 依托单位:
Predictability of chemosensitivity of histoculture drug response assays and status of p53 gene for organ preservation therapy using neoadjuvant chemotherapy in patients with head and neck carcinomas
  • 批准号:
    11671719
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $1.98万
  • 财政年份:
    1999
  • 负责人:
    HASEGAWA Yasuhisa
  • 依托单位:
国内基金
海外基金
IFN-γ信号激活通过自噬缓解CDDP诱导的心脏毒性
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    曹莹莹
  • 依托单位:
负载COS/CDDP的同轴纳米纤维气凝胶双载药系统在卵巢癌治疗中的作用
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2022
  • 负责人:
  • 依托单位: